Alison Skrinar

4.1k total citations · 1 hit paper
50 papers, 1.5k citations indexed

About

Alison Skrinar is a scholar working on Physiology, Nephrology and Epidemiology. According to data from OpenAlex, Alison Skrinar has authored 50 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Physiology, 14 papers in Nephrology and 11 papers in Epidemiology. Recurrent topics in Alison Skrinar's work include Parathyroid Disorders and Treatments (14 papers), Lysosomal Storage Disorders Research (14 papers) and Cerebral Palsy and Movement Disorders (8 papers). Alison Skrinar is often cited by papers focused on Parathyroid Disorders and Treatments (14 papers), Lysosomal Storage Disorders Research (14 papers) and Cerebral Palsy and Movement Disorders (8 papers). Alison Skrinar collaborates with scholars based in United States, United Kingdom and France. Alison Skrinar's co-authors include Javier San Martín, Erik A. Imel, Thomas O. Carpenter, Meng Mao, Michael P. Whyte, Agnès Linglart, Stephen M. Haley, Emil Kakkis, Wolfgang Högler and Raja Padidela and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Alison Skrinar

48 papers receiving 1.4k citations

Hit Papers

Burosumab Therapy in Children with X-Linked Hypophosphatemia 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Burosumab Therapy in Children with X-Linked Hypophosphatemia
    2018 321 citations Thomas O. Carpenter, Michael P. Whyte et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alison Skrinar United States 21 691 426 414 272 254 50 1.5k
V. Braga Italy 27 217 0.3× 188 0.4× 254 0.6× 827 3.0× 224 0.9× 54 2.1k
Anya Rothenbühler France 23 784 1.1× 268 0.6× 95 0.2× 407 1.5× 61 0.2× 83 1.6k
Mohd Shazli Draman United Kingdom 21 326 0.5× 116 0.3× 120 0.3× 66 0.2× 95 0.4× 36 1.4k
G. Luisetto Italy 23 197 0.3× 84 0.2× 133 0.3× 410 1.5× 195 0.8× 74 1.6k
Wendy Marder United States 21 98 0.1× 908 2.1× 150 0.4× 92 0.3× 144 0.6× 52 1.6k
J.C. Souberbielle France 19 271 0.4× 71 0.2× 103 0.2× 156 0.6× 45 0.2× 44 1.3k
Maryann Mitnick United States 14 233 0.3× 61 0.1× 180 0.4× 557 2.0× 75 0.3× 18 1.2k
Klaus Mohnike Germany 27 200 0.3× 113 0.3× 64 0.2× 233 0.9× 166 0.7× 112 2.0k
Paul Meisner United States 11 176 0.3× 154 0.4× 177 0.4× 1.3k 4.9× 118 0.5× 14 2.7k
Bert‐Ove Olofsson Sweden 18 167 0.2× 55 0.1× 246 0.6× 110 0.4× 163 0.6× 33 1.2k

Countries citing papers authored by Alison Skrinar

Since Specialization
Citations

This map shows the geographic impact of Alison Skrinar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Skrinar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Skrinar more than expected).

Fields of papers citing papers by Alison Skrinar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Skrinar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Skrinar. The network helps show where Alison Skrinar may publish in the future.

Co-authorship network of co-authors of Alison Skrinar

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Skrinar. A scholar is included among the top collaborators of Alison Skrinar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Skrinar. Alison Skrinar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ward, Leanne M., Francis H. Glorieux, Michael P. Whyte, et al.. (2022). Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia. The Journal of Clinical Endocrinology & Metabolism. 107(8). e3241–e3253. 41 indexed citations
2.
Linglart, Agnès, Erik A. Imel, Michael P. Whyte, et al.. (2021). Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia. The Journal of Clinical Endocrinology & Metabolism. 107(3). 813–824. 53 indexed citations
3.
Lochmüller, Hanns, Anthony Béhin, Ivailo Tournev, et al.. (2021). Results from a 3-year Non-interventional, Observational Disease Monitoring Program in Adults with GNE Myopathy. Journal of Neuromuscular Diseases. 8(2). 225–234. 10 indexed citations
4.
Nixon, Andrew, Angela Williams, Alison Skrinar, & Christina Theodore‐Oklota. (2019). PRO153 PSYCHOMETRIC VALIDATION OF THE PROMIS PHYSICAL FUNCTION MOBILITY, PAIN INTERFERENCE AND FATIGUE IN A COHORT OF PAEDIATRIC X-LINKED HYPOPHOSPHATEMIA (XLH) PATIENTS. Value in Health. 22. S870–S870.
5.
Thacher, Tom D., John Μ. Pettifor, Peter J. Tebben, et al.. (2019). Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score. Bone. 122. 76–81. 48 indexed citations
6.
7.
8.
Chan, Yiu-mo, et al.. (2017). Substantial deficiency of free sialic acid in muscles of patients with GNE myopathy and in a mouse model. PLoS ONE. 12(3). e0173261–e0173261. 12 indexed citations
9.
Argov, Zohar, Antonio Esposito, Julaine Florence, et al.. (2017). Characterization of Strength and Function in Ambulatory Adults With GNE Myopathy. Journal of Clinical Neuromuscular Disease. 19(1). 19–26. 9 indexed citations
10.
Argov, Zohar, Yoseph Caraco, Heather Lau, et al.. (2016). Aceneuramic Acid Extended Release Administration Maintains Upper Limb Muscle Strength in a 48-week Study of Subjects with GNE Myopathy: Results from a Phase 2, Randomized, Controlled Study. Journal of Neuromuscular Diseases. 3(1). 49–66. 32 indexed citations
11.
Shapiro, Elsa, Heather Adams, Ann Barbier, et al.. (2016). Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions. Molecular Genetics and Metabolism. 118(2). 65–69. 26 indexed citations
12.
Whyte, MP, et al.. (2012). Fracture Burden In Adults With Hypophosphatasia. Revistes Científiques de la University of Barcelona (University of Barcelona). 51(1). 15. 1 indexed citations
13.
Wokke, John H. J., Diana M. Escolar, Alan Pestronk, et al.. (2008). Clinical features of late‐onset Pompe disease: A prospective cohort study. Muscle & Nerve. 38(4). 1236–1245. 132 indexed citations
14.
Kallwass, Helmut, Robert J. Pomponio, Deeksha Bali, et al.. (2007). Rapid diagnosis of late-onset Pompe disease by fluorometric assay of α-glucosidase activities in dried blood spots. Molecular Genetics and Metabolism. 90(4). 449–452. 46 indexed citations
15.
Jaffe, Kenneth M., John H. J. Wokke, Pascal Laforêt, et al.. (2007). M.P.2.05 Late onset Pompe disease is associated with impaired pulmonary and muscle function and diminished health-related quality of life. Neuromuscular Disorders. 17(9-10). 794–794. 1 indexed citations
16.
Weinreb, Neal J., J. A. Barranger, Seymour Packman, et al.. (2007). Imiglucerase (Cerezyme®) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clinical Genetics. 71(6). 576–588. 76 indexed citations
17.
Haley, Stephen M., et al.. (2006). A physical performance measure for individuals with mucopolysaccharidosis type I. Developmental Medicine & Child Neurology. 48(7). 576–576. 17 indexed citations
18.
Haley, Stephen M., et al.. (2005). The Emerging Role of the Pediatric Physical Therapist in Evaluation and Intervention for Individuals with Lysosomal Storage Diseases. Pediatric Physical Therapy. 17(2). 128–139. 2 indexed citations
19.
Dumas, Helene M., et al.. (2004). Physical performance testing in mucopolysaccharidosis I: a pilot study. Pediatric Rehabilitation. 7(2). 125–131. 21 indexed citations
20.
Haley, Stephen M., Maria A. Fragala-Pinkham, Pengsheng Ni, Alison Skrinar, & Edward M. Kaye. (2004). Pediatric physical functioning reference curves. Pediatric Neurology. 31(5). 333–341. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by V. Braga Breakdown of academic impact, for papers by Anya Rothenbühler Breakdown of academic impact, for papers by Mohd Shazli Draman Breakdown of academic impact, for papers by G. Luisetto Breakdown of academic impact, for papers by Wendy Marder Breakdown of academic impact, for papers by J.C. Souberbielle Breakdown of academic impact, for papers by Maryann Mitnick Breakdown of academic impact, for papers by Klaus Mohnike Breakdown of academic impact, for papers by Paul Meisner Breakdown of academic impact, for papers by Bert‐Ove Olofsson
Rankless by CCL
2026